JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - ABCELLERA BIOLOGICS INC
Explicit Guidance:
- Regulatory Milestones: Expect to begin Phase 3 registrational studies "mid-ish" next year (late 2026/early 2027) following regulatory alignment and CMC completion.
- Clinical Data Readouts: Plans to disclose 12-week washout data and open-label extension (OLE) results (showing second dose efficacy) "early next year."
- Pipeline Advancement: Two additional assets (ABCL-688 and ABCL-386) in IND-enabling activities with a target entry into the clinic in the current year (2026).
- Liquidity: Current liquidity of approximately $900 million (plus real estate ownership) cited as sufficient to fund Phase 3 and parallel pipeline development.
Business-Segment Outlook:
- Lead Asset (ABCL-635): Anticipates defining the treatment of hot flashes via a non-hormonal approach; efficacy data (frequency twice, severity 4–5x better than small molecules) supports a potential shift from the original Target Product Profile (TPP) of "equal efficacy/better safety" to superior efficacy.
- Indication Expansion: Phase 3 design to cover vasomotor symptoms (VMS) in menopause and parallel studies planned for cancer-related VMS (prostate and breast cancer).
- Secondary Asset (ABCL-992): Half-life extended analog of ABCL-635; currently in development to achieve "at least once-quarterly dosing," serving as a life-cycle management tool and defensive measure against competitor follow-ons.
- Platform Value: Commitment to advancing undisclosed oncology and ion channel programs (ABCL-385, ABCL-646) to demonstrate platform capability in previously "out of reach" targets.
- Commercial Strategy: Exploring a hybrid commercial model including Direct-to-Consumer (DTC) and telehealth channels; not currently seeking partners for late-stage development, but open to partnerships for commercialization or DTC execution.
Market and Competitive Outlook:
- Competitive Landscape: Projects competitors will attempt to develop half-life extended versions of similar NK3R antagonists; Avcelera aims to leverage 20 years of patent life and aggressive IP protection to maintain first-mover advantage.
- Pricing Power: Anticipates strong case for pricing premiums over current small-molecule standards of care ($5,000 annually) due to superior efficacy, safety (no liver toxicity), and convenience.
- Market Dynamics: Sees potential for "complete resolution" of symptoms (37% in Phase 2) as a key differentiator; notes that cancer-related VMS market is currently overlooked but represents a large, underserved patient population.
- Product Positioning: Views ABCL-635 and ABCL-992 as co-existing products with potential for distinct dosing intervals (monthly vs. quarterly) rather than immediate replacement.
Macro / Industry Outlook:
- Regulatory Environment: Managing CMC requirements for auto-injector/pre-filled syringe delivery; expects alignment with FDA/EMA to proceed without friction despite Phase 2 data being generated in Canada (92 patients, <12 sites).
- Healthcare Economics: Considering "physician choice" head-to-head trials vs. standard care (SSRIs, SNRIs, gabapentin) for real-world evidence, though registrational studies will likely remain placebo-controlled per current standards for VMS.
- Safety Perception: Anticipates clear regulatory differentiation from small molecules regarding hepatotoxicity risks, leveraging the biological distinction that antibodies do not undergo liver metabolism.
Strategic Initiatives:
- CMC Acceleration: Rapidly scaling manufacturing for auto-injector/pre-filled syringe formats (150 mg/mL concentration, 2mL volume = 300mg dose); views this as the primary rate-limiting step before Phase 3 start.
- Team Building: Fully committed to building a late-stage development and commercial team to operate independently; not seeking external capital or partnerships for the core asset development.
- Product Optimization: Development of ABCL-992 specifically to address potential future competition and optimize dosing frequency (quarterly) to improve patient compliance and cost of goods for a high-volume product.
- Pipeline Ramp-up: Moving from "hired gun" contract research services (ramped down in 2023) to full internal biotech model with multiple assets advancing to clinical trials.
Risks and Headwinds to Outlook:
- Efficacy Variance: Management acknowledges a potential waning of efficacy during the 12-week washout period; investors are cautioned not to over-interpret lower efficacy at the 12-week mark compared to the 4-week peak.
- Adverse Events: Ongoing monitoring of headache frequency (reported as mild, self-resolving, median duration 1 day); expectation is that headaches may not recur upon second dosing, but this is not yet confirmed.
- Regulatory Path: Final dose selection and study design pending Post-Phase 2 meetings with FDA and EMA; delays in CMC or regulatory alignment could push Phase 3 start beyond the "mid-next year" window.
- Market Competition: Risk of "breakthrough data" attracting rapid follow-on products or half-life extensions from other biotech firms, necessitating continued IP defensibility.
- Safety Signal Reversal: Uncertainty regarding long-term safety profile (e.g., anti-antibody responses, liver enzymes) over a treatment duration of ~7 years (median menopause duration).
Management Tone on the Future:
- Confidence Level: Highly optimistic ("data blew the doors off," "knocked people's socks off"), expressing strong belief in the product's ability to "redefine" treatment standards.
- Strategic Shift: Tone reflects a decisive pivot from CRO services to blockbuster biotech, characterized by aggression in moving assets through trials and a willingness to invest heavily in commercial infrastructure.
- Risk Management: Pragmatic and transparent; management explicitly sets expectations for data nuances (washout periods, safety profiles) to prevent investor misinterpretation of early metrics.
- Long-Term Vision: Emphasizes a "blockbuster" potential for ABCL-635 and a platform capable of repeatedly inventing and commercializing medicines, aiming for a sustained pipeline of assets beyond the lead candidate.
Miscellaneous:
- Study Design Nuance: Phase 2 single dose (600mg) mimics steady-state of a future once-monthly 300mg injection; 8-week follow-up is purely for exposure-response modeling and washout, not primary efficacy assessment.
- Dosing Assumptions: Current TPP assumes a single 300mg shot once monthly; potential for lower doses or less frequent intervals (quarterly) to be confirmed by OLE data.
- Geographic Strategy: Initial trials in Canada used for rapid recruitment; full intention to conduct Phase 3 in the US and other jurisdictions.
- Asset Naming: Lead asset is ABCL-635; half-life extended analog is ABCL-992; future pipeline includes ABCL-688, ABCL-386, ABCL-385, and ABCL-646.
- Company
- ABCELLERA BIOLOGICS INC
- Keywords
- ABCELLERA BIOLOGICS INC